Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground

Schizophrenia Research

Volumn 16, Issue 2, 1995, Pages 87-110

  Weinberger, Daniel R ^a   Lipska, Barbara K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

(Schizophrenia); C fos; Clozapine; Cortex; Development; Dopamine

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

BRAIN CORTEX; DEVELOPMENTAL DISORDER; DOPAMINERGIC SYSTEM; HUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RESEARCH; REVIEW; SCHIZOPHRENIA;

ANIMAL; ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HUMAN; NEURAL PATHWAYS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0029149615     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0920-9964(95)00013-C     Document Type: Article

References (213)

1. Fos and Jun cooperate in transcriptional regulation via heterologous activation domains
2. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenic implies disturbances of cortical development
3. Typical and atypical antipsychotic occupancy of D-2 and S-2 receptors: An autoradiographic analysis in rat brain
4. The hippocampus and parahippocampus in schizophrenic, suicide, and control brains
5. Effect of clozapine on turnover of dopamine in the corpus striatum and in the limbic system
6. Evidence for different states of the dopamine D1 receptor: Clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor
7. Magnetic resonance imaging of the brain in schizophrenia: The pathophysiologic significance of structural abnormalities
8. Structural abnormalities in the frontal system in schizophrenia
9. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with Xenon133 single-photon emission computed tomography and the Tower of London
10. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia
11. Pharmacology of mesocortical dopamine neurons
12. Development of the hippocampal region in the rat. I. Neurogenesis examined with 3H-thymidine autoradiography
13. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients
14. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics
15. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients
16. Functional localization in the brain in schizophrenia
17. Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia
18. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia
19. Basal ganglia and limbic system pathology in schizophrenia: A morphometric study of brain volume and shrinkage
20. Third-ventricle enlargement and neuropsychological deficit in schizophrenia
21. A detailed mapping of dopamine D2 receptors in rat central nervous system by autoradiography with [125]iodosulpiride
22. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA
23. Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs
24. Sensorimotor gating and schizophrenia
25. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results
26. Effects of ibotenic acid lesion of medial prefrontal cortex on dopamine agonist-related behaviors in the rat
27. Brain morphology and schizophrenia: A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures
28. Neurodevelopmental implications of findings from brain imaging studies of schizophrenia
29. Postmortem evidence of structural brain changes in schizophrenia
30. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia
31. Clozapine induces Fos expression in pyramidal cells and interneurons in the prefrontal cortex in regionally specific manner
32. Dopamine theory revisited
33. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?
34. Neuroleptic drug effects on cognitive function in schizophrenia
35. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: Implications for drug mechanisms of action
36. Context, cortex and dopamine: A connectionist approach to behavior and biology in schizophrenia
37. Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation
38. Quantitative cytoarchitectonics of the human cerebral cortex in schizophrenic dementia
39. Limbic/mesolimbic connections and the pathogenesis of schizophrenia
40. Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics
41. Time-locked multiregional retroactivation: A systems-level proposal for the neural substrates of recall and recognition
42. Reduction in temporal lobe size in siblings with schizophrenia: A magnetic resonance imaging study
43. Dopamine in schizophrenia: A review and reconceptualization
44. Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats
45. Schizophrenia-like psychoses associated with organic disorders of the central nervous system
46. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
47. Antipsychotic drug effects on Fos protein in the prefrontal cortex: Cellular localization and pharmacology
48. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action
49. Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies in schizophrenia
50. Selective induction of Fos and FRA immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields
51. Cognitive impairment associated with morphological brain abnormalities in computed tomography in chronic schizophrenic patients
52. The use of c-fos as a metabolic marker in neuronal pathway tracing
53. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons
54. Neuropsychological evidence for frontostriatal dysfunction in schizophrenia
55. D-1 and D-2-receptor occupancy during treatment with conventional and atypical neuroleptics
56. Anatomical and electrophysiological evidence for a direct projection from Ammon's horn to the medial prefrontal cortex in the rat
57. Effects of typical and atypical neuroloeptics on Fos protein expression in the rat forebrain
58. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs
59. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia
60. The relationship of brain imaging parameters to antipsychotic treatment response: A review
61. Towards a neuropsychology of schizophrenia
62. The long and the short of long-term memory-a molecular framework
63. The effects of haloperidol on thought disorder and IQ in schizophrenia
64. Schizophrenia and temporal lobe epilepsy: A neuropsychological study
65. The performance of patients with schizophrenia on the Wechsler Memory Scale-Revised
66. Neuropsychological functioning and time-linked information processing in schizophrenia
67. Contrasts between patients with affective disorder and patients with schizophrenia on a neoropsychological screening battery
68. The impact of clozapine on cognition and psychiatric symptoms in patients with schizophrenia
69. Neuropsychological assessment of monozygotic twins discordant for schizophrenia
70. Learning and memory in monozygotic twins discordant for schizophrenia
71. Further evidence for dementia of the prefrotnal type in schizophrenia
72. Circuitry of primate prefrontal cortex and regulation of behavior by representational memory
73. The circuitry of working memory revealed by anatomy and metabolic imaging
74. The primitive mediodorsal (MD) nucleus and its project to the frontal lobe
75. The neurobiology of cognitive development
76. Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey
77. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
78. The neuropsychology of schizophrenia
79. Neurochemically specified subsystems in the basal ganglia
80. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum
81. Organization of projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of Phaseolus vulgaris leucoagglutinin
82. Magnetic resonance imaging in schizophrenia: I. Volumetric analysis of brain and cerebrospinal fluid
83. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiviing clozapine
84. Mechanism of complex transcriptional regulation: implications for brain development
85. Specificity in the projection patterns of accumbal core and shell in the rat
86. Neuropsychological functioning of first-episode schizophreniform patients
87. Interaction of psychotropic drugs with central 5-HT-3 recognition sites: fact or artifact?
88. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1c and 5-HT2 recognition sites
89. Neuroanatomical and neurochemical pathology in schizophrenia
90. Psychiatric disturbances in metachromatic leukodystrophy: Insight into the neurobiology of psychosis
91. Prenatal developmental disturbances in the limbic allocortex in schizophrenics
92. Dopamine and schizophrenia: A cortically corrective perspective
93. Ibotenic acid lesions of medial prefrontal cortex augment swim-stress induced locomotion
94. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia
95. Hippocampal pathologic findings in schizophrenia
96. Cognitive impairment in schizophrenia: Specific relations to ventricular size and negative symptomatology
97. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde- and retrograde-horseradish peroxidase study
98. Topographic localization of Fos positive nuclei in nucleus accumbens projection neurons
99. Performance of schizophrenic patients on tests sensitive to left or right frontal temporal, and parietal function in neurologic patients
100. Role of the cyclic AMP-dependent protein kinase in signal transduction
101. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography
102. Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: Involvement of alpha1-noradrenergic receptors demonstrated by in vivo voltammetry
103. Schizophrenic dementia: Clinical and CT correlates
104. The effects of atypical antipsychotic drug on striatal fos expression
105. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor number in the rat brain
106. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-Propyl-2-aminotetralin
107. The secondary schizophrenias
108. [3H]Ketanserin (R41468), a selective [3H]ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role
109. Brain imaging
110. Qualitative assessment of brain morphology in acute and chronic schizophrenia
111. Time course and biologic correlates of treatment response in first-episode schizophrenia
112. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia: Prevalence and clinical correlates
113. Delayed behavioral disturbances associated with neonatal excitotoxic hippocampal damage in the rat: Effects of castration and neuroleptics
114. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat
115. Genetic differences in behavioral response to neonatal hippocampal damage in rats
116. Gonadectomy does not prevent novelty or drug-induced motor hyperresponsiveness in rats with neonatal hippocampal damage
117. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
118. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia
119. The effects of combined prefrontal cortical and hippocampal damage on dopamine-related behaviors in rats
120. Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat
121. Neonatal excototoxic hippocampal damage disrupts sensorimotor gating in postpubertal rats
122. Quantitative effects of typical and typical neuroleptics on smooth pursuit eye tracking in schizophrenia
123. Lateral ventricular size, psychopathology, and medication response in the psychoses
124. Some psychiatric implications of physiological studies on frontotemporal portion of limbic system (visceral brain)
125. Dopaminergic stimulation disrupts sensorimotor gating in the rat
126. Differential distribution of D2 and D4 dopamine receptor mRNAs in the rat brain: An situ hybridization study
127. Localization of D4 and D5 dopamine receptor mRNAs in the human brain
128. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia
129. Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2, and serotonin2 pKi values
130. Differential induction of c-fos mRNA in rat prefrontal cortex by typical versus atypical antipsychotics
131. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions
132. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rats neostriatum
133. Large-scale neurocognitive networks and distributed processing for attention, language, and memory
134. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs
135. Acute effect of typical and atypical anti-psychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum in the rat: An in vivo microdialysis study
136. The role of ion flux in the control of c-fos
137. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun
138. Visualization of dopamine D3-like receptors in human brain with [125I]epidepride
139. The problem of the frontal lobe: A reinterpretation
140. Differential expression of c-fos and Zif 268 in rat striatum following haloperidol, clozapine, amphetamine
141. Dopamine receptor genes: New tools for molecular psychiatry
142. Synaptic interactions among excitatory afferents to nucleus accumbens neurons Hippocampal gating of prefrontal cortical input
143. Post-mortem study of chronic schizophrenic brains
144. Prefrontal cortex in relation to other cortical areas in rhesus monkey: Architecture and connections
145. A proposed mechanism of emotion
146. Differential visualization of dopamine D2 and D3 receptors in rat brain
147. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors
148. Ventricle-brain ratio, computed tomographic density, and brain area in 50 schizophrenics
149. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia
150. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: Implications for regional brain dysfunction in schizophrenia
151. Stimulatory effect of the D2 antagonist sulpiride on glucose utilization in dopaminergic regions of rat brain
152. Molecular basis of different forms of metachromatic leukodystrophy
153. Localization of cognitive operations in the human brain
154. An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures
155. Specification of cerebral cortical areas
156. The neuropsychology of schizophrenia
157. Release from proactive interference Determinants of performance and neuropsychological correlates
158. Cerebral ventricular size in twins discordant for schizophrenia
159. Chronic clozapine treatment of rats down regulates cortical 5-HT2 receptors
160. Sulcal prominence in young chronic schizophrenia patients: CT scan findings associated with impairment in neuropsychological tests
161. A ‘mock up’ of schizophrenia: Temporal lobe epilepsy and schizophrenia-like psychosis
162. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine
163. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
164. The hippocampal formation of the primate brain A review of some comparative aspects of cytoarchitecture and connections
165. Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder: A regional cerebral blood flow study
166. Expression of c-fos protein in brain: Metabolic mapping at the cellular level
167. Dopamine receptors in the prefronal cortex: Involvement in working memory
168. Neuropsychological function in schizophrenia: Selective impairment in memory and learning
169. Three-dimensional steric molecular modeling of the 5-hydroxytryptamine 3 receptor pharmacophore
170. Early lesions and abnormal neuronal connections: Developmental rules can lead axons astray, with functional consequences
171. Dopamine receptor sequences. Tharapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4
172. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area
173. The topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study using Phaseolus vulgaris leucoagglutinin
174. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other
175. Cerebral structural pathology in schizophrenia: Evidence for a selective prefrontal cortical deficit
176. The regulation and function of c-fos and other immediate early genes in the nervous system
177. Pharmacology of human D3 receptor expressed in a mammalian cell line: comparison with D2 receptor
178. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
179. The medial temporal lobe memory system
180. The development of the hippocampal region
181. An anatomy of schizophrenia?
182. Mechanism for diversity in gene expression patterns
183. Temporal lobe pathology in schizophrenia: A quantitative MRI study
184. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia
185. Dopamine schizophrenia mania and depression Toward a unified hypothesis of cortico-striato-pallido-thalamic function
186. Central dopamine hyperactivity in rats mimicks abnormal acoustic startle response in schizophrenics
187. Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects
188. Factors influencing the occurrence of schizophrenia-like psychoses in temporal lobe epilepsy
189. Cognitive dysfunction in schizophrenia
190. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients
191. Development of connections between the mediodorsal nucleus of the thalamus and the prefrontal cortex in the rat
192. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
193. Electrophysiological evidence that the mediodorsal nucleus of the thalamus is a relay between the ventral pallidum and the prefrontal cortex in the rat
194. Brain organization in schizophrenia
195. Implications of normal brain development for the pathogenesis of schizophrenia
196. Anteriomedial temporal-prefrontal connectivity: A functional anatomical system implicated in schizophrenia
197. A connectionist approach to the prefrontal cortex
198. Schizophrenia as a neurodevelopmental disorder
199. Speculation on the meaning of cerebral metabolic ‘hypofrontality’ in schizophrenia
200. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism
201. Disorganization of prefrontal-hippocampal connectivity in schizophrenia: A PET studies of discordant MZ twins
202. Evidence for dysfunction of a prefrontal-limbic network in schizophrenia: An MRI and rCBF study of discordant monozygotic twins
203. Cerebral ventricular enlargement in chronic schizophrenia: Association with poor response to treatment
204. Familial aspects of CT abnormalities in chronic schizophrenic patients
205. Computed tomography scans in schizophreniform disorder and other acute psychiatric patients
206. Structural abnormalities of the cerebral cortex in chronic schizophrenia
207. Altered relationships between metabolic rates of glucose in brain regions of schizophrenic patients
208. Cocaine induces striatal c-Fos-immunoreactive proteins via dopaminergic D1 receptors
209. The relationship between CT scan findings and neuropsychological performance in chronic schizophrenia
210. In vivo studies of brain morphology in patients with schizophrenia
211. Widespread cerebral gray matter volume deficits in schizophrenia
212. Effect of thioridazine, clozapine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in striatum and nucleus accumbens